Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T11:51:16.150Z.
Calculation as of: 2026-10-06T11:51:16.150Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7bb4fe4bb3aa983eb4620adc8aa5d0f555a5020ff21ce65ee2b72f9631e0f85
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$2.87B
EBITDA Yield
3.62%
TTM Avg
2.99%
3Y Avg
2.18%
5Y Avg
2.18%
Market Cap
$2.69B
EBITDA Yield
7.55%
TTM Avg
8.87%
3Y Avg
7.02%
5Y Avg
6.94%
Market Cap
$2.69B
EBITDA Yield
10.53%
TTM Avg
12.59%
3Y Avg
12.00%
5Y Avg
11.83%
Market Cap
$3.09B
EBITDA Yield
N/A
TTM Avg
127.06%
3Y Avg
127.06%
5Y Avg
127.06%
Market Cap
$3.15B
EBITDA Yield
1.15%
TTM Avg
0.54%
3Y Avg
0.54%
5Y Avg
0.54%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.88B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 3.62% | 2.99% | 2.18% | 2.18% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 1.25% | 1.25% | 1.25% | 1.25% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 7.55% | 8.87% | 7.02% | 6.94% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 10.53% | 12.59% | 12.00% | 11.83% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | N/A | 127.06% | 127.06% | 127.06% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 1.15% | 0.54% | 0.54% | 0.54% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A | 0.89% | 0.89% | 0.89% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
